Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Luis Castro Pineiro Int'l Appln. No. PCT/GB2004/001435 Int'l Date Filed 1 April 2004 (04/01/2004) Serial No.: (To be assigned) Case No.: T1610YP Filed October 3, 2005 For COMBINATION THERAPY FOR ALZHEIMER'S DISEASE Commissioner for Patents

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

Alexandria, Virginia 22313-1450

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

BATE OF DEPOSIT

CTO GET 2 2005

EXPRESS MAIL NO.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSED TO

COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313, 1450.

MAILED BY

DATE

CTOOLS 3, 2005

JC05 Rec'd PCT/PTO 03 OCT 2005

Serial No.: Case No.: To be assigned T1610YP

Page

10/2507

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted

⁷ - \ / / - - -

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: October 3, 2005

					Tatell and Tradellark Office, 0.3 DELTAKTINETT OF COMMERCE	
Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application And Rec'd PCT/PTO 33 OCT 2005		
				Filing Date	October 3, 20 0/.5.52367	
STATEMENT BY AFFLICANT			FLICANI	First Named Inventor	Jose Luis Castro Pineiro	
	(Group Art Unit		
(use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	T1610YP	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	·	US 5,767,124		Michael J. Kaufman et al	06/16/1998
				,	
					· · · · · · · · · · · · · · · · · · ·
		, , , , , , , , , , , , , , , , , , , ,			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Office	Foreign Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			WO 03/018579	T	Merck Frosst Canada & Co.	03/06/2004
			WO 02/060897		Merck & Co., Inc.	08/08/2002
			WO 02/069970		Merck & Co., Inc. & Merck Frosst Canada & Co.	09/12/2002

Examiner Signature	Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.